| Intended Product Classification | FIBC should be specified for non-dangerous solid pharmaceutical ingredients, excipients, intermediates, or finished powders unless a separate hazardous-goods design is required. | Define product name, powder characteristics, bulk density, moisture sensitivity, oxygen sensitivity, filling temperature, and maximum storage period. | Product risk assessment, material compatibility review, and written technical specification. | Prevents the use of a general-purpose bulk bag where a higher level of contamination, static, or moisture control is required. |
| Applicable FIBC Standard | Design and performance should be aligned with ISO 21898 for flexible intermediate bulk containers used with non-dangerous goods. | Specify bag type, construction, lifting arrangement, discharge system, filling system, and rated capacity. | Design drawings, product specification, batch inspection records, and applicable performance test reports. | Creates a consistent technical baseline for purchasing, qualification, and incoming inspection across international markets. |
| Safe Working Load | Common pharmaceutical FIBC capacities are approximately 500–2,000 kg, depending on construction and handling equipment. | Declare the exact Safe Working Load, bag factor, number of lifting cycles, and whether the container is intended for single-trip or reusable service. | Load-bearing test, top-lift test, seam-strength test, and documented safety-factor calculation. | Ensures safe lifting, transport, and storage while avoiding overloading of the bag or warehouse equipment. |
| Safety Factor | Safety factors of 5:1 or 6:1 are commonly specified for FIBC construction; the final value depends on reuse and handling conditions. | 5:1 for defined single-trip applications or 6:1 where repeated handling or additional safety margin is required. | Third-party or in-house tensile, top-lift, and cyclic-lift testing supported by a controlled test method. | Allows buyers to match bag construction with the actual handling cycle instead of relying only on nominal capacity. |
| Fabric and Coating | Use woven polypropylene fabric with a documented resin specification; coated or uncoated construction should be selected according to powder leakage and moisture requirements. | Record fabric basis weight, denier, tensile strength, elongation, coating type, coating weight, and permeability requirements. | Raw-material certificates, fabric inspection, tensile testing, visual inspection, and coating-weight verification. | Controls mechanical strength, dust retention, product loss, and resistance to humidity during international transportation. |
| Inner Liner | Use a compatible polyethylene liner when enhanced containment, moisture protection, or low-product-retention performance is required. | Specify liner resin, thickness, dimensions, fit, sealing method, anti-static properties, and whether the liner is removable or integrated. | Material certificate, thickness measurement, leak test, seal-strength test, and compatibility assessment with the packed product. | Reduces contamination and powder leakage risks and supports more reliable discharge of fine pharmaceutical powders. |
| Clean Manufacturing | Production should take place in a controlled environment with documented cleaning, personnel hygiene, pest control, and foreign-matter prevention procedures. | Define room classification or cleanliness target, gowning rules, cleaning frequency, environmental monitoring, and packaging controls. | Site audit, cleaning records, environmental-monitoring records, hygiene procedures, and foreign-material control logs. | Pharmaceutical buyers need evidence that the bag is manufactured under controlled conditions rather than only visually clean at dispatch. |
| Bioburden and Microbiological Control | Microbiological limits should be established according to the drug product, manufacturing process, and quality-risk assessment. | Define sampling plan, alert and action limits, test frequency, handling of nonconforming results, and laboratory responsibility. | Validated or qualified microbiological methods, routine test reports, trend analysis, and corrective-action records. | Supports contamination-control strategies for sensitive pharmaceutical materials without automatically implying sterility. |
| Sterility Requirement | FIBC should not be described as sterile unless a validated sterilization process, sterile packaging system, and release procedure are provided. | For aseptic applications, specify sterilization method, sterility assurance level, packaging integrity, and validated shelf life. | Sterilization validation, dose or cycle records, sterility testing where applicable, packaging-integrity testing, and release certification. | Prevents misleading claims and ensures that sterile-use requirements are treated separately from ordinary pharmaceutical-grade cleanliness. |
| Electrostatic Control | Static-control construction should be selected according to powder explosibility, solvent exposure, filling equipment, and grounding procedures. | Specify Type A, B, C, or D FIBC classification where applicable; define grounding resistance, conductive yarn arrangement, and operating procedure. | Surface-resistance or continuity testing, grounding verification, electrostatic-control documentation, and process risk assessment. | Reduces ignition and electrostatic-discharge risks when handling combustible dusts or flammable atmospheres. |
| Product Contact Materials | All product-contact materials should be identified, traceable, and suitable for the intended pharmaceutical application. | List polymer type, additives, pigments, sewing thread, liner material, elastomers, and any processing aids. | Material declarations, supplier certificates, extractables or leachables assessment where justified, and change-control records. | Provides traceability and supports regulatory, toxicological, and compatibility evaluations by the finished-product manufacturer. |
| Extractables and Leachables | Assessment should be risk-based and focused on materials that contact the pharmaceutical product or can transfer contaminants. | Define extraction solvents, temperature, contact time, surface-area-to-volume ratio, and analytical limits where testing is required. | Material composition review, laboratory extraction study, analytical report, and toxicological evaluation when applicable. | Helps identify chemical migration risks that may not be detected by routine visual or mechanical inspections. |
| Particulate and Fiber Control | Bag construction should minimize loose fibers, plastic flakes, sewing debris, and other visible or non-visible particulate contamination. | Specify internal cleanliness, trimming requirements, loose-thread limits, inspection lighting, and vacuum or air-cleaning procedure. | Visual inspection records, particle-counting method where required, internal cleanliness inspection, and batch-release checklist. | Important for powders used in products where visible particles or foreign matter can cause batch rejection. |
| Filling and Discharge Design | Inlet and outlet design should match the filling line, discharge equipment, powder flow behavior, and containment requirements. | Define inlet and outlet diameter, spout length, closure type, liner configuration, discharge rate target, and residual-product limit. | Dimensional inspection, fit test on production equipment, discharge trial, and powder-retention assessment. | Improves line efficiency, operator safety, yield, and containment during transfer of pharmaceutical powders. |
| Traceability and Batch Coding | Each production batch should be traceable to raw materials, manufacturing dates, operators, inspection results, and release status. | Use batch number, production date, material lot, inspection status, quantity, and unique packaging identification. | Batch records, certificate of conformity, certificate of analysis where applicable, and controlled label samples. | Enables effective recall, deviation investigation, supplier performance monitoring, and regulatory inspection readiness. |
| Quality Management System | A documented quality system should control purchasing, production, inspection, deviations, complaints, CAPA, training, and change management. | Require documented procedures, internal audits, training records, nonconformance handling, CAPA, and formal change notification. | Quality-system questionnaire, audit report, controlled procedures, CAPA samples, and change-control procedure. | Shows whether the supplier can provide repeatable quality rather than a one-time conforming sample. |
| Packaging and Transport Protection | FIBC should be protected from moisture, dust, UV exposure, compression damage, and accidental opening during storage and shipment. | Specify outer packaging, pallet configuration, wrapping, desiccant use where justified, maximum storage conditions, and transport orientation. | Packaging specification, pallet inspection, transit simulation where necessary, and shipping-condition records. | Maintains cleanliness and mechanical integrity from supplier dispatch through receipt at the pharmaceutical facility. |
| Shelf-Life and Storage | Storage conditions should protect polypropylene fabric, liners, closures, and labels from excessive heat, humidity, sunlight, and contamination. | Define temperature range, relative humidity target, UV exposure limits, stacking restrictions, and recommended storage period. | Stability or aging assessment where needed, storage instructions, warehouse records, and packaging-integrity checks. | Reduces deterioration before use, particularly during long international supply chains and extended warehouse storage. |
| Supplier Qualification | Qualification should combine document review, facility audit, sample approval, process validation, and ongoing performance monitoring. | Assess technical capability, clean-production controls, testing capacity, lead time, minimum order quantity, continuity planning, and complaint response. | Supplier questionnaire, quality agreement, audit report, approved sample, first-article inspection, and periodic review. | Helps global buyers compare OEM suppliers using objective evidence instead of price, catalog claims, or sample appearance alone. |
